MedTrace Logo

Neural Responses and Dysphoria: Modulation by a Pharmacological Probe

NCT01101685 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2011-06-07

No results posted yet for this study

Summary

This study aims to improve understanding of how people with low mood and negative feelings (known as dysphoric) may be different from people with normal mood and feelings (nondysphoric) when responding to a variety of social and emotional information. The study will look at the patterns of activity in peoples' brains in situations (presented as a battery of tests) after treatment with a medicine (escitalopram) or a placebo. The results from this study will help to gather information about the effectiveness of the various tests being used in this study in detecting any changes due to treatment with an antidepressant. Half the volunteers taking part in this study will be dysphoric (mildly depressed) whilst the other half of volunteers will be healthy volunteers. It is hoped that the results of this study will provide guidance for assessing effectiveness of new medicines and potentially help with the treatment of depression.

Conditions

  • Dysphoria

Interventions

DRUG

Escitalopram

7 days dosing of 10mg per day

DRUG

Placebo

7 days dosing at 10mg daily

Sponsors & Collaborators

  • P1vital Limited

    collaborator INDUSTRY

  • University of Manchester

    collaborator OTHER

  • Institute of Psychiatry, London

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Guy Goodwin · University of Oxford

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01101685 on ClinicalTrials.gov